Description

Calumid (bicalutamide) coated tablets 50 mg. №30

Ingredients

Active ingredient: Bicalutamide 50 mg.
Other ingredients: lactose monohydrate, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, talc.

Dosage

Recommended dosage: The usual dose is one 50 mg tablet taken once daily, with or without food. Follow your healthcare provider’s instructions.

Indications

Calumid tablets are indicated for the treatment of prostate cancer in combination with a luteinizing hormone-releasing hormone (LHRH) analog.

Contraindications

Do not take Calumid tablets if you are allergic to bicalutamide or any other ingredients in the product. Consult your doctor before use if you have liver problems.

Directions

Take Calumid tablets exactly as prescribed by your healthcare provider. Do not exceed the recommended dosage. Swallow the tablet whole with a glass of water.

Scientific Evidence

Bicalutamide, the active ingredient in Calumid tablets, is a nonsteroidal antiandrogen that competitively inhibits the action of androgens. Studies have shown that bicalutamide, when used in combination with an LHRH analog, is effective in the treatment of prostate cancer by blocking the androgen receptors.

Additional Information

It is important to attend regular follow-up appointments with your healthcare provider while taking Calumid tablets to monitor your response to treatment and any potential side effects. Inform your doctor of any new symptoms or changes in your health.

Pharmacological Effects: Bicalutamide works by blocking the effects of androgens, which are male hormones that can promote the growth of prostate cancer cells. By inhibiting the androgen receptors, bicalutamide helps slow down the progression of the disease.

Clinical Trials: Clinical trials have demonstrated the efficacy of bicalutamide in improving overall survival rates and delaying disease progression in patients with advanced prostate cancer. One study published in the New England Journal of Medicine showed a significant reduction in the risk of disease progression with bicalutamide treatment.